Lansoprazole in the treatment of functional dyspepsia: Two double-blind, randomized, placebo-controlled trials

American Journal of Medicine

Volumn 116, Issue 11, 2004, Pages 740-748

  Peura, David A ^a,f   Kovacs, Thomas O G ^b   Metz, David C ^c   Siepman, Nancy ^d   Pilmer, Betsy L ^d   Talley, Nicholas J ^e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; DUODENUM ULCER; DYSPEPSIA; ESOPHAGITIS; FEMALE; FUNCTIONAL DISEASE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECORDING; RECURRENT DISEASE; REFLUX ESOPHAGITIS; SCREENING; SELF REPORT; STOMACH EROSION; STOMACH ULCER; SYMPTOM;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSPEPSIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 2442442748     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2004.01.008     Document Type: Article

References (39)

1. Talley N.J., Colin-Jones D., Koch K.L., et al. Functional dyspepsia a classification with guidelines for diagnosis and management. Gastroenterol Int. 4:1991;145-160
2. Jones R., Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ. 298:1989;30-32
3. Tougas G., Chen Y., Hwan P., et al. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population findings from the DIGEST study. Domestic/International Gastroenterology Surveillance Study. Am J Gastroenterol. 94:1999;2845-2854
4. Gilvarry J., Buckley M.J., Beattie S., et al. Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol. 32:1997;535-540
5. Blum A.L., Talley N.J., O'Morain C., et al. Lack of effect of treating Helicobacter pylori infection in patients with non-ulcer dyspepsia. Omeprazole plus clarithromycin and amoxicillin effect one year after treatment (OCAY) study group. N Engl J Med. 339:1998;1875-1881
6. McColl K.E., Murray L., El-Omar E., et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 339:1998;1869-1874
7. Talley N.J., Janssens J., Lauritsen K., et al. Eradication of Helicobacter pylori in functional dyspepsia randomized, double-blind, placebo-controlled trial with 12 months' follow up. The optimal regimen cures Helicobacter pylori induced dyspepsia (ORCHID) study group. BMJ. 318:1999;833-837
8. Laine L., Schoenfeld P., Fennerty M.B. Therapy for Helicobacter pylori in patients with non-ulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med. 134:2001;361-369
9. Talley N.J., Vakil N., Ballard E.D., Fennerty M.B. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 341:1999;1106-1111
10. Moayyedi P., Soo S., Deeks J., et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ. 321:2000;659-664
11. Nyren O., Adami H.O., Gustavsson S., et al. The epigastric distress syndrome. A possible disease entity identified by history and endoscopy in patients with nonulcer dyspepsia. J Clin Gastroenterol. 9:1987;303-309
12. Finney J.S., Kinnersley N., Hughes M., et al. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol. 26:1998;312-320
13. Bytzer P. H2 receptor antagonists and prokinetics in dyspepsia a critical review. Gut. 50:(suppl IV):2002;58-62
14. Redstone H.A., Barrowman N., Veldhuyzen van Zanten S.J. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther. 15:2001;1291-1299
15. Lachman L., Howden C.W. Twenty-four-hour intragastric pH tolerance within five days of continuous ranitidine administration. Am J Gastroenterol. 95:2000;57-61
16. Hunt R.H. Importance of pH control in the management of GERD. Arch Intern Med. 159:1999;649-657
17. Smith J.L., Operkun A.R., Larkai E., Graham D.Y. Sensitivity of esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology. 96:1989;683-689
18. Chiba N., De Gara C.J., Wilkinson J.M., Hunt R.H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease a meta-analysis. Gastroenterology. 112:1997;1798-1810
19. Howden C.W., Burget D.W., Hunt R.H. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl. 201:1994;79-82
20. Talley N.J., Meineche-Schmidt V., Pare P., et al. Efficacy of omeprazole in functional dyspepsia double-blind, randomized, placebo-controlled trial (the Bond and Opera studies). Aliment Pharmacol Ther. 12:1998;1055-1065
21. Wong W.M., Wong B.C.Y., Hung W.K., et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut. 51:2002;502-506
22. Thompson W.G., Dotevall G., Drossman D.A., et al. Irritable bowel syndrome guidelines for the diagnosis. Gastroenterol Int. 2:1989;92-95
23. Hetzel D.J., Dent J., Reed W.D., et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 95:1988;903-912
24. Cowell H., Mathias S.D., Pasta D.J., et al. Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease. Dig Dis Sci. 44:1999;1376-1383
25. Veldehuyzen van Zanten S.J., Cleary C., Talley N.J., et al. Drug treatment of functional dyspepsia a systematic analysis of trial methodology and recommendations for design of future trials. Am J Gastroenterol. 91:1996;660-673
26. Benson V., Marano M.A. Current estimates from the National Health Interview Survey, 1995. National Center for Health Statistics. Vital Health Stat. 199:1998;1-498
27. Talley N.J., Zinmeister A.R., Schleck C.D., Melton L.J.I. Dyspepsia and dyspepsia subgroups a population-based study. Gastroenterology. 102:1992;1259-1268
28. Drossman D.A., Li Z., Andruzzi E., et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci. 38:1993;1569-1580
29. Lydeard S., Jones R. Factors affecting the decision to consult with dyspepsia comparison of consulters and non-consulters. J R Coll Gen Pract. 39:1989;495-498
30. Frank L.B., Kleinman L., Ganoczy D.A., et al. Upper gastrointestinal symptoms in North America prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci. 45:2000;809-818
31. Kagevi I., Lofstedt S., Persson L.G. Endoscopic findings and diagnoses in unselected dyspeptic patients at a primary health care center. Scand J Gastroenterol. 24:1989;145-150
32. Talley N.J., Phillips S.F. Non ulcer dyspepsia potential causes and pathophysiology. Ann Intern Med. 108:1988;865-879
33. Saunders J.H., Oliver R.J., Higson D.L. Dyspepsia incidence of non-ulcer disease in a controlled trial of ranitidine in general practice. BMJ. 292:1986;665-668
34. Dobrilla G., Comberlato M., Steele A., Vallaperta P. Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled trials. J Clin Gastroenterol. 11:1989;169-177
35. Meineche-Schmidt V., Krag E. Relief of symptoms in patients with reflux or ulcer-like dyspepsia after two weeks treatment with either omeprazole, cimetidine, or placebo - a Danish multicenter trial in general practice. Eur J Gen Pract. 3:1997;125-130
36. Richter J.E., Campbell D.R., Kahrilas P.J., et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 160:2000;1803-1809
37. Castell D.O., Richter J.E., Robinson M., et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol. 91:1996;1749-1757
38. Chiba N., Veldhuyzen van Zanten J.O., Sinclair P., Ferguson R.A., Escobedo S., Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomized controlled trial. BMJ. 324:2002;1012-1018
39. Talley N.J., Stanghellii V., Heading R.C., Koch K.L., Malagelada J.R., Tytgat G.N.J. Functional gastroduodenal disorders. Gut. 45:(suppl II):1999;II37-II42